Navigation Links
Cepheid Announces Accelerated Development of Flu A Panel Test
Date:9/9/2009

applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market. See www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the timing of new product releases, the timing and likelihood of regulatory review and approval, product performance, and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen product development and manufacturing problems; uncertainties in the regulatory review process for new products; regulatory developments and practices regarding testing; customer and market acceptance of the product; the failure of the product to perform as expected, whether due to manufacturing errors, design defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the product; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2008 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    CONTACTS:
    F
'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Reports 2009 Second Quarter Results
3. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
4. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
5. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
6. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
7. Blue Mountain Quality Resources Announces that Cepheid has Selected Blue Mountain Regulatory Asset Manager
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By product ... Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), End ... studies the major market drivers, restraints, opportunities and ... Rest of the world (RoW). , The ... $3.58 billion by 2019 from $2.4 billion in ...
(Date:3/31/2015)... Safeware has been recognized ... Central Ohio, an awards program presented by Columbus Business ... the awards program, held on March 10, 2015. These ... health, with outstanding health and wellness initiatives. , ... a healthy environment for their associates. Business Frist, OhioHealth ...
(Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
(Date:3/31/2015)... A' Design Award and Competition is pleased ... Daniel Dion has been announced as a winner of ... Devices and Research Equipment Design Competition Category. ... behind the award winning Medical Product design Bruker EVOQ ... direction of Dr. Rohan Thakur and the Bruker team ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today that third ... third quarter 2006 revenue of $23.4,million. Revenue from Osteotech,s ... for the three months ended September 30,2007 as compared ... for the,third quarter of 2006. Gross margin improved to ...
... 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... Cameron Groome, Executive,Vice-President, Corporate & Strategic Development, will ... Healthcare Conference in New York City,tomorrow. Mr. Groome ... the Holmes,II Room of the New York Palace ...
... by web cast-, TORONTO, Nov. 6 /PRNewswire-FirstCall/ ... in the research,development and commercialization of pharmaceutical products ... that on,Wednesday, November 7, 2007, at 10:30 a.m. ... and CEO will present a corporate overview of ...
... Elite Books, TUCSON, Ariz., Nov. 5 We all ... the development of Alzheimer,s Disease and heart,disease, along with a ... In her seminal book, The Apo E Gene Diet: ... Body,s Own Genes,(Elite, Hardcover, $27.95, November 1, 2007), Pamela McDonald, ...
... 5 StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: ... Administration ("FDA"), through its Center for Devices and,Radiological ... Laboratory,Improvements Amendments of 1988 ("CLIA") for an HIV ... The HIV 1/2 product,is marketed and distributed worldwide ...
... offices could ... YORK, Nov. 5 Group Health Incorporated (GHI) and,HIP ... educational seminar in,New York City on November 6 for ... be held at HIP,headquarters, 55 Water St., will provide ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference 2Health News:Groundbreaking Apo E Gene Diet Linked to Alzheimer's Disease and Heart Disease Prevention 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3Health News:GHI and HIP Lead Effort to Expand Electronic Health Record System Throughout the City of New York 2
(Date:3/31/2015)... March 31, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" ... premium quality medical marijuana products and a licensed producer ... Purposes Regulations ( Canada ) ("MMPR"), is ... The Corporation of the District of Saanich ... Company,s premises which now allows for commercial distribution of ...
(Date:3/31/2015)... -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: ... its planned bullous pemphigoid (BP) clinical development for bertilimumab, ... is an orphan auto-immune blistering disease of the skin ... Europe . As previously announced, ... II clinical trial in Israel ...
(Date:3/31/2015)... , March 31, 2015 ANI Pharmaceuticals, Inc. ... of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, ... The overall US market for Propafenone Hydrochloride 150mg, 225mg ... IMS Health. Arthur S. Przybyl , ... to announce the launch of our fourth product from ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... ROYAL OAK, Mich., March 4, 2011 Doctors ... minimally invasive robotic procedure to correct atrial fibrillation, ... new robotic maze procedure is an alternative to ... with fewer complications and a shorter hospital stay. ...
... March 4, 2011 The pressure for a new ... with organizations across the pharmaceutical sector facing pipeline deficits, ... Facing an ever-changing launch landscape, product launch leaders are ... therapies through the labyrinth of regulatory and marketplace challenges. ...
Cached Medicine Technology:Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 3Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: